A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Abroad (travel likely)RecruitingPHASE1

Conditions

IgA Nephropathy · Focal Segmental Glomerulosclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongda Hospital, Affiliated to Southeast University, Nanjing, Jiangsu, China
Contact: Study coordinator (Ren Zhou) · zdll2015@163.com · 025-83272015

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Minimal Change Disease (MCD) · IgA Nephropathy (IgAN) · Focal Segmental Glomerulosclerosis (FSGS)

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Tianjin, China

Raman Spectroscopy Diagnosis of Kidney Diseases

IgA Nephropathy (IgAN) · Membranous Nephropathy · Diabetic Nephropathy

Abroad (travel likely)Recruiting

Jinan, China

National Registry of Rare Kidney Diseases

Adenine Phosphoribosyltransferase Deficiency · AH Amyloidosis · AHL Amyloidosis

Abroad (travel likely)Recruiting

Bristol, United Kingdom

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Glomerular Disease · Minimal Change Disease · IgA Nephropathy

Abroad (travel likely)Recruiting

Chuncheon, South Korea · Daegu, South Korea